^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BI 1361849

    i
    Other names: BI 1361849, CV-9202, CV9202, CV 9202
    Associations

    News

    Trials
    Company:
    CureVac
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    almost3years
    Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC (clinicaltrials.gov)
    P1/2, N=59, Completed, Ludwig Institute for Cancer Research | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Oct 2021
    Clinical • Trial completion • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK mutation • ROS1 mutation
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab) • BI 1361849
    over3years
    Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC (clinicaltrials.gov)
    P1/2, N=56, Active, not recruiting, Ludwig Institute for Cancer Research | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2021 --> Oct 2021
    Clinical • Enrollment closed • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK mutation • ROS1 mutation
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab) • BI 1361849 • self-amplifying RNA cancer vaccine
    over4years
    Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. (PubMed, J Immunother Cancer)
    The results support further investigation of mRNA-based immunotherapy in NSCLC including combinations with immune checkpoint inhibitors.
    Clinical • P1 data • Journal
    |
    MUC1 (Mucin 1) • BIRC5 (Baculoviral IAP repeat containing 5)
    |
    EGFR mutation
    |
    pemetrexed • BI 1361849